<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="156511">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02056392</url>
  </required_header>
  <id_info>
    <org_study_id>D1532C00071</org_study_id>
    <nct_id>NCT02056392</nct_id>
  </id_info>
  <brief_title>To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers</brief_title>
  <official_title>A Phase I, Double-blind (Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), Placebo-controlled, Open-Label (Moxifloxacin) Positive-controlled, Randomized, Three-period Crossover Study to Assess the Effects of Single Oral Dose of Selumetinib (75 mg) on QTc Interval Compared to Placebo, Using AVELOX (Moxifloxacin) as a Positive Control, in Healthy Male Volunteers Aged 18 to 45 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to assess the effect of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc
      interval in healthy male volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A double-blind (Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), Placebo-controlled,
      Open-Label (Moxifloxacin) Positive-controlled, Randomized, Three-period Crossover Study to
      Assess the Effects of Single Oral Dose of Selumetinib (75 mg) on QTc Interval Compared to
      Placebo, using AVELOX (Moxifloxacin) as a Positive Control, in Healthy Male Volunteers
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Effect of a single dose of selumetinib (75 mg) on the change in time-matched QTcF interval compared to placebo.</measure>
    <time_frame>Digital ECGs recorded pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post dose</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Performed during each of the 3 treatments</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of selumetinib, N-desmethyl selumetinib, and moxifloxacin by assessment of area under the plasma concentration-time from time zero to infinity (AUC)</measure>
    <time_frame>Blood samples are collected pre dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48 hours post dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Curve taken during each of the 3 treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of selumetinib, N-desmethyl selumetinib, and moxifloxacin by assessment of area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration AUC(0-t)</measure>
    <time_frame>Blood samples are collected pre dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48 hours post dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Curve taken during each of the 3 treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of selumetinib and moxifloxacin only, by assessment of apparent volume of distribution at equilibrium, mean residence time (MRT)*CL/F (Vss/F)</measure>
    <time_frame>Blood samples are collected pre dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48 hours post dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Curve taken during each of the 3 treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of selumetinib and moxifloxacin only, by assessment of apparent systemic plasma clearance (CL/F)</measure>
    <time_frame>Blood samples are collected pre dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48 hours post dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Curve taken during each of the 3 treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of selumetinib, N-desmethyl selumetinib, and moxifloxacin by assessment of apparent terminal phase of volume at distribution (selumetinib and moxifloxacin only) (Vz/F)</measure>
    <time_frame>Blood samples are collected pre dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48 hours post dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Curve taken during each of the 3 treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of selumetinib, N-desmethyl selumetinib, and moxifloxacin by assessment of terminal half-life (t1/2).</measure>
    <time_frame>Blood samples are collected pre dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48 hours post dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Curve taken during each of the 3 treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of selumetinib, N-desmethyl selumetinib, and moxifloxacin by assessment of terminal rate constant (λz)</measure>
    <time_frame>Blood samples are collected pre dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48 hours post dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Curve taken during each of the 3 treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of selumetinib, N-desmethyl selumetinib, and moxifloxacin by assessment of mean residence time (MRT)</measure>
    <time_frame>Blood samples are collected pre dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48 hours post dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Curve taken during each of the 3 treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of selumetinib and N-desmethyl selumetinib by assessment of AUC metabolite to parent ratio, N-desmethyl selumetinib (MRAUC)</measure>
    <time_frame>Blood samples are collected pre dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48 hours post dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Curve taken during each of the 3 treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of selumetinib and N-desmethyl selumetinib by assessment of Cmax metabolite to parent ratio, N-desmethyl selumetinib (MRCmax)</measure>
    <time_frame>Blood samples are collected pre dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48 hours post dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Curve taken during each of the 3 treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of selumetinib, N-desmethyl selumetinib, and moxifloxacin by assessment of time to Cmax (tmax).</measure>
    <time_frame>Blood samples are collected pre dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48 hours post dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Curve taken during each of the 3 treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of selumetinib, N-desmethyl selumetinib, and moxifloxacin by assessment of maximum plasma concentration (Cmax)</measure>
    <time_frame>Blood samples are collected pre dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48 hours post dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Curve taken during each of the 3 treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of selumetinib on additional ECG variables (QT, HR, RR, QRS, PR) and QTcB</measure>
    <time_frame>Digital ECGs recorded pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post dose</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Performed during each of the 3 treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The maximum of the mean changes in time-matched QTcF interval after moxifloxacin administration compared to placebo</measure>
    <time_frame>Digital ECGs recorded pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post dose</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Performed during each of the 3 treatments</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety variables (adverse events, physical examinations, ophthalmic assessments, vital signs, clinical laboratory assessments and 12 lead electrocardiograms)</measure>
    <time_frame>Baseline (Day -1) up to Day 28</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Assessments performed during each of the 3 treatments</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Solid Tumours</condition>
  <arm_group>
    <arm_group_label>Selumetinib 75mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volunteers will receive selumetinib 75mg administered by mouth, as a capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moxifloxacin 400 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Volunteers will receive moxifloxacin 400mg administered by mouth, as a capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Selumetinib 75mg placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Volunteers will receive selumetinib 75mg placebo, administered by mouth, as a capsule.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selumetinib</intervention_name>
    <description>Volunteers will receive 75 mg selumetinib oral dose (Treatment A)</description>
    <arm_group_label>Selumetinib 75mg</arm_group_label>
    <other_name>AZD6244</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>Volunteers will receive 400 mg Moxifloxacin oral dose (Treatment B)</description>
    <arm_group_label>Moxifloxacin 400 mg</arm_group_label>
    <other_name>Avelox®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>selumetinib</intervention_name>
    <description>Volunteers will receive selumetinib placebo oral dose (Treatment C)</description>
    <arm_group_label>Selumetinib 75mg placebo</arm_group_label>
    <other_name>AZD6244</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: 1. Have a body mass index (BMI) between 18 and 30 kg/m2 and weigh at
        least 50 kg and no more than 100 kg (inclusive). 2. Must  have not smoked in the last 30
        days prior to screening for this study. 3. Have a calculated creatinine clearance (CrCL)
        greater than 50 mL/min using the Cockcroft-Gault formula.

        Exclusion Criteria: 1. Subjects of Japanese or non-Japanese Asian ethnicity. 2. Subjects
        where any one parent or grandparent (maternal or paternal) is Japanese or non-Japanese
        Asian (e.g. China, Taiwan, Korea, Philippines, Thailand, Vietnam, and Malaysia). Asian
        Indians are acceptable. 3. Past history of central serous retinopathy or retinal vein
        thrombosis,intraocular pressure greater than 21 mmHg or uncontrolled glaucoma. 4. Any
        clinically relevant abnormal findings in physical examination, hematology, clinical
        chemistry, urinalysis, vital signs or ECG at baseline in the opinion of the investigator.
        5. History or presence of any clinically significant disease or disorder in the opinion of
        the investigator.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott Rasmussen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles 6700 W 115th Street, Kansas, US</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Quintiles Drug Research Unit Call Centre</last_name>
    <phone>0800 634 1132</phone>
    <email>ClinicalTrialTransparency@astrazeneca.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 27, 2014</lastchanged_date>
  <firstreceived_date>February 5, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase I, healthy, pharmacokinetics</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
